Pheochromocytoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Medical Therapy== | ==Medical Therapy== | ||
Any surgical option requires prior treatment with both the non-specific alpha adrenoceptor blocker [[ | Any surgical option requires prior treatment with both the non-specific alpha adrenoceptor blocker [[phenoxybenzamine]] to counteract hypertension and the beta-1 adrenoceptor antagonist [[atenolol]] to reduce cardiac output. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour removal, which would otherwise endanger the anaethetised patient. | ||
==References== | ==References== | ||
Revision as of 16:22, 11 September 2012
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma medical therapy |
|
Risk calculators and risk factors for Pheochromocytoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Any surgical option requires prior treatment with both the non-specific alpha adrenoceptor blocker phenoxybenzamine to counteract hypertension and the beta-1 adrenoceptor antagonist atenolol to reduce cardiac output. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour removal, which would otherwise endanger the anaethetised patient.